Treatment with the ETA-receptor antagonist FR 139317 limited the increase in systolic blood pressure to 212 mm Hg compared to 260 mm Hg in control stroke-prone spontaneously hypertensive rats.
Absolute Event Rate: 212% vs 260%
The cardiovascular consequences of endothelin (ET) blockade with the ETA-receptor antagonist FR 139317 were evaluated by determining the long-term effects of the drug on hemodynamic, hormonal, renal and structural parameters in stroke-prone spontaneously hypertensive rats (SHR-SP). Young SHR-SP on a high-sodium diet develop malignant hypertension accompanied by renovascular and cerebrovascular lesions. In control SHR-SP the systolic blood pressure increased from 196 +/- 3 to 260 +/- 4 mm Hg, whereas in animals treated with FR 139317 (20 mg/kg intraperitoneally, twice daily) it increased only from 196 +/- 4 to 212 +/- 3 mm Hg during a treatment period of 6 weeks. There was also an increase in heart weight. At the end of the experiment the plasma levels of atrial natriuretic peptide and brain natriuretic peptide were significantly lower in the group treated with FR 139317 than in the controls. The endothelin plasma levels were significantly higher and the plasma renin activity was lower in the group treated with the endothelin receptor antagonist. These data indicate that endothelin is involved in the maintenance of high blood pressure and cardiac hypertrophy in malignant hypertension, as exemplified by SHR-SP.
Stasch et al. (Wed,) conducted a other in Malignant hypertension and cardiac hypertrophy. FR 139317 vs. Control SHR-SP was evaluated on Systolic blood pressure. Treatment with the ETA-receptor antagonist FR 139317 limited the increase in systolic blood pressure to 212 mm Hg compared to 260 mm Hg in control stroke-prone spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: